Evidence map›Paper›PMID 35042868›Full record

Trial reportScientific reports2022

A 6-mRNA host response classifier in whole blood predicts outcomes in COVID-19 and other acute viral infections.

Ljubomir Buturovic, Hong Zheng, Benjamin Tang, Kevin Lai, Win Sen Kuan, Mark Gillett, Rahul Santram, Maryam Shojaei, Raquel Almansa, Jose Ángel Nieto and 22 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Alterations in Immune-Related Defensin Alpha 4 (International journal of inflammation · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 9 institutions in 5 countries.

Ljubomir Buturovic *Inflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Hong Zheng *Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Benjamin TangCentre for Immunology and Allergy Research, Westmead Institute for Medical Research, Sydney, Australia.
Kevin LaiDepartment of Emergency Medicine, Westmead Hospital, Sydney, Australia.
Win Sen KuanDepartment of Emergency Medicine, National University Hospital Singapore, Singapore, Singapore.
Mark GillettDepartment of Emergency Medicine, Royal North Shore Hospital, Sydney, Australia.
Rahul SantramDepartment of Emergency Medicine, St Vincent Hospital, Sydney, Australia.
Maryam ShojaeiCentre for Immunology and Allergy Research, Westmead Institute for Medical Research, Sydney, Australia.
Raquel AlmansaGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Jose Ángel NietoServicio de Urgencias de Atención Primaria, Salamanca, Spain.
Sonsoles MuñozServicio de Urgencias de Atención Primaria, Salamanca, Spain.
Carmen HerreroServicio de Urgencias de Atención Primaria, Salamanca, Spain.
Nikolaos Antonakos4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62, Athens, Greece.
Panayiotis Koufargyris4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62, Athens, Greece.
Marina Kontogiorgi4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62, Athens, Greece.
Georgia Damoraki4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62, Athens, Greece.
Oliver LiesenfeldInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
James WackerInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Uros MidicInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Roland LuethyInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
David RawlingInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Melissa RemmelInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Sabrina CoyleInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Yiran E LiuInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Aditya M RaoInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Denis DermadiInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Jiaying TohInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Lara Murphy JonesInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Michele DonatoInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Purvesh KhatriInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62, Athens, Greece.
Timothy E SweeneyInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA. tsweeney@inflammatix.com.
Stanford University · USNational and Kapodistrian University of Athens · GRWestmead Institute for Medical Research · AUHospital Universitario Río Hortega · ESNational University Hospital · SGRoyal North Shore Hospital · AUStanford Medicine · USSt Vincent's Hospital Sydney · AUWestmead Hospital · AU

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Systems biological assessment of T cell responses to vaccinationU19AI167903 · NIAID · STANFORD UNIVERSITY · PI BALI PULENDRAN · 2022 to 2026
$13.2M
NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI167903
6 · The paper itself

Abstract

Predicting the severity of COVID-19 remains an unmet medical need. Our objective was to develop a blood-based host-gene-expression classifier for the severity of viral infections and validate it in independent data, including COVID-19. We developed a logistic regression-based classifier for the severity of viral infections and validated it in multiple viral infection settings including COVID-19. We used training data (N = 705) from 21 retrospective transcriptomic clinical studies of influenza and other viral illnesses looking at a preselected panel of host immune response messenger RNAs. We selected 6 host RNAs and trained logistic regression classifier with a cross-validation area under curve of 0.90 for predicting 30-day mortality in viral illnesses. Next, in 1417 samples across 21 independent retrospective cohorts the locked 6-RNA classifier had an area under curve of 0.94 for discriminating patients with severe vs. non-severe infection. Next, in independent cohorts of prospectively (N = 97) and retrospectively (N = 100) enrolled patients with confirmed COVID-19, the classifier had an area under curve of 0.89 and 0.87, respectively, for identifying patients with severe respiratory failure or 30-day mortality. Finally, we developed a loop-mediated isothermal gene expression assay for the 6-messenger-RNA panel to facilitate implementation as a rapid assay. With further study, the classifier could assist in the risk assessment of COVID-19 and other acute viral infections patients to determine severity and level of care, thereby improving patient management and reducing healthcare burden.

Indexed as

COVID-19Gene Expression RegulationAcute DiseaseFemaleHumansMaleMiddle AgedPredictive Value of TestsRetrospective StudiesRNA, MessengerSARS-CoV-2RNA, Messenger

Identifiers

PMID35042868
PMCPMC8766462
OpenAlexW4205179063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.